Drug Trial News

RSS

Microbix renegotiates key terms of Hunan influenza vaccine joint venture

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and biological products announced today that it is renegotiating key terms of the original joint venture agreement with their Joint Venture partner Hunan Biopharmaceutical Co. Ltd.

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Anacor Pharmaceuticals announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

28 Jun 2011

New and effective diabetes drug seeking approval

A new drug for diabetes from Bristol-Myers Squibb Co. and AstraZeneca PLC was effective in lowering blood sugar. The pharmaceutical drug makers are looking for approval for the drug, dapagliflozin, as the first in new class of pills designed to lower blood sugar by increasing the amount of glucose excreted in the urine.

27 Jun 2011

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

27 Jun 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc. today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.

27 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

FDA responds to EpiCept Ceplene SPA

EpiCept Corporation today announced that it has received initial written responses from the U.S. Food and Drug Administration regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene (histamine dihydrochloride) Phase III protocol.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

Drug Trial News

Microbix renegotiates key terms of Hunan influenza vaccine joint venture

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

New and effective diabetes drug seeking approval

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Cardium to purchase Transdel's business assets

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

FDA responds to EpiCept Ceplene SPA

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Positive results from Stealth's Bendavia Phase I renal impairment study

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News